Digest Network Come funziona
Network
/
Società
Ep
Non verificato

EpiBiologics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

4 comunicati stampa

Guarda tutti i comunicati
19/04/2026
Eventi
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Scienza
Medicina - Varie
EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors
Fonte
EpiBiologics
Emittente
Business Wire
1.00
0
08/01/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology
Fonte
EpiBiologics
Emittente
Business Wire
1.00
0
28/04/2025
Industria
Oncologia
Salute
Biologia
Scienza
Biotecnologia
EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody
Fonte
EpiBiologics
Emittente
Business Wire
1.00
0
04/11/2024
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Oncologia
EpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings
Fonte
EpiBiologics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0